SCHEMBL2179047

SCHEMBL2179047

Fc1c(Br)ccc2ncccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.58
KDM4E B2RXH2 3/20 0.58
CYP3A4 P08684 1/20 0.47
HTT P42858 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HSP90AA1 P07900 3/20 0.46
LMNA P02545 2/20 0.46
HSP90AB1 P08238 2/20 0.46
BLM P54132 1/20 0.46
HIF1A Q16665 1/20 0.46
AXL P30530 1/20 0.44
ALDH1A1 P00352 3/20 0.42
APAF1 O14727 2/20 0.42
TDP2 O95551 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
ERN1 O75460 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4054902 0.79 KDM4E (0.62) MAPTKDM4ECYP3A4HTTMEN1
SCHEMBL30387307 0.79 KDM4E (0.62) MAPTKDM4ECYP3A4HTTMEN1
SCHEMBL18070695 0.76 MAPT (0.58) MAPTKDM4ECYP3A4HTTMEN1
SCHEMBL24936440 0.76 MAPT (0.66) MAPTKDM4ECYP3A4HTTMEN1
SCHEMBL12121729 0.76 MAPT (0.58) MAPTKDM4ECYP3A4HTTMEN1
SCHEMBL12101512 0.76 MAPT (0.58) MAPTKDM4ECYP3A4HTTMEN1
SCHEMBL1133974 0.76 KDM4E (0.58) MAPTKDM4ECYP3A4HTTMEN1
SCHEMBL14242728 0.76 KDM4E (0.58) MAPTKDM4ECYP3A4HTTMEN1
SCHEMBL13692757 0.76 MAPT (0.58) MAPTKDM4ECYP3A4HTTMEN1
SCHEMBL30694275 0.76 MAPT (0.58) MAPTKDM4ECYP3A4HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 WO disclosed
US-20250099462-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor HUTCHISON MEDIPHARMA LTD (CN) 2025-03-27 US disclosed
WO-2025064853-A1 RIPK3 INHIBITORS AND METHODS OF USE Momentum Therapeutics, Inc. (US) 2025-03-27 WO disclosed
US-20250092031-A1 RIPK3 INHIBITORS AND METHODS OF USE INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2025-03-20 US disclosed
US-20240139182-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor HUTCHISON MEDIPHARMA LTD (CN) 2024-05-02 US disclosed
US-11896592-B2 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor HUTCHISON MEDIPHARMA LIMITED (CN) 2024-02-13 US disclosed
US-20240002375-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE REMIX THERAPEUTICS INC. 2024-01-04 US disclosed
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-12-12 US disclosed
CN-117015536-A 2- (indazol-5-yl) -6- (piperidin-4-yl) -1, 7-naphthyridine derivatives and related compounds as modulators of nucleic acid splicing and treatment of proliferative diseases 雷密克斯医疗公司 2023-11-07 CN disclosed
EP-4175956-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES Remix Therapeutics Inc. (US) 2023-05-10 EP disclosed
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-10-15 US disclosed
CN-101558070-A Triazolopyridazine protein kinase modulators SGX PHARMACEUTICALS INC (US) 2009-10-14 CN disclosed
CN-101553490-A Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS INC (US) 2009-10-07 CN disclosed
EP-2084162-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-08-05 EP disclosed
EP-2081937-A2 TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-07-29 EP disclosed
US-20090156594-A1 HETEROCYCLIC KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-06-18 US disclosed
WO-2008144767-A1 HETEROCYCLIC KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-11-27 WO disclosed
WO-2008051805-A2 TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 WO disclosed
WO-2008051808-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 WO disclosed
WO-2008051808-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092031-A1 RIPK3 INHIBITORS AND METHODS OF USE RIPK3, RIPK1, RIPK2 MAPT 2485/4885KDM4E 3072/4885CYP3A4 4785/4885
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 MAPT 4627/4885KDM4E 1571/4885CYP3A4 144/4885
US-20240002375-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE POLRMT, HNRNPA1, SNRPA MAPT 2126/4885KDM4E 3380/4885CYP3A4 4552/4885
US-11896592-B2 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor TK2, TYMP, DPYD MAPT 3970/4885KDM4E 3641/4885CYP3A4 339/4885
US-20090156594-A1 HETEROCYCLIC KINASE MODULATORS MAP3K20, MAP4K2, MAP3K13 MAPT 2253/4885KDM4E 992/4885CYP3A4 3956/4885
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS MAP3K20, TTK, PRKACB MAPT 1886/4885KDM4E 1566/4885CYP3A4 2246/4885
US-20250099462-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor KCNJ11, NISCH, CYP4Z1 MAPT 3267/4885KDM4E 4236/4885CYP3A4 52/4885
US-20240139182-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor KCNJ11, NISCH, CYP4Z1 MAPT 3267/4885KDM4E 4236/4885CYP3A4 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.